A Randomized Controlled Trial of Motivational Interviewing as a Tool to Enhance Secondary Prevention Strategies in Cardiovascular Disease (MICIS Study)

2021 ◽  
pp. 1-30
Author(s):  
B. Everett ◽  
Y. Salamonson ◽  
B. Koirala ◽  
R. Zecchin ◽  
PM. Davidson
2020 ◽  
Vol 11 ◽  
pp. 215013272092271 ◽  
Author(s):  
Amanda T. Sawyer ◽  
Jo Wheeler ◽  
Pamela Jennelle ◽  
Julie Pepe ◽  
Patricia Stearnes Robinson

The purpose of this randomized controlled trial was to examine the effects of a motivational interviewing intervention to improve whole-person lifestyle and reduce cardiovascular disease risk profile. A sample of 111 adults with type 2 diabetes and/or hypertension was recruited from a primary care physician practice. The intervention was facilitated by a program specialist trained in motivational interviewing. Outcomes included body mass index, cholesterol, hemoglobin A1c, blood pressure, waist circumference, wellness scores, and substance use. Differences in the changes in body mass index and waist circumference existed between the intervention and control groups after 6 months. In the intervention group, the proportion of high wellness scores increased after the program. A whole-person lifestyle intervention with motivational interviewing for patients with metabolic syndrome can improve one’s health in terms of components in the cardiovascular disease risk profile, as well as overall wellness. Efforts to improve the health of these patients may incorporate motivational interviewing to guide goal setting and address mental and spiritual health in addition to physical health.


2021 ◽  
Vol 223 ◽  
pp. 108716
Author(s):  
Elizabeth J. Santa Ana ◽  
Steven D. LaRowe ◽  
Mulugeta Gebregziabher ◽  
Antonio A. Morgan-Lopez ◽  
Kayla Lamb ◽  
...  

Epilepsia ◽  
2019 ◽  
Vol 60 (5) ◽  
pp. 986-995 ◽  
Author(s):  
Benjamin Tolchin ◽  
Gaston Baslet ◽  
Joji Suzuki ◽  
Steve Martino ◽  
Hal Blumenfeld ◽  
...  

Author(s):  
Ferdows Atiq ◽  
Jens van de Wouw ◽  
Oana Sorop ◽  
Ilkka Heinonen ◽  
Moniek P. M. de Maat ◽  
...  

AbstractIt is well known that high von Willebrand factor (VWF) and factor VIII (FVIII) levels are associated with an increased risk of cardiovascular disease. It is still debated whether VWF and FVIII are biomarkers of endothelial dysfunction and atherosclerosis or whether they have a direct causative role. Therefore, we aimed to unravel the pathophysiological pathways of increased VWF and FVIII levels associated with cardiovascular risk factors. First, we performed a randomized controlled trial in 34 Göttingen miniswine. Diabetes mellitus (DM) was induced with streptozotocin and hypercholesterolemia (HC) via a high-fat diet in 18 swine (DM + HC), while 16 healthy swine served as controls. After 5 months of follow-up, FVIII activity (FVIII:C) was significantly higher in DM + HC swine (5.85 IU/mL [5.00–6.81]) compared with controls (4.57 [3.76–5.40], p = 0.010), whereas VWF antigen (VWF:Ag) was similar (respectively 0.34 IU/mL [0.28–0.39] vs. 0.34 [0.31–0.38], p = 0.644). DM + HC swine had no endothelial dysfunction or atherosclerosis during this short-term follow-up. Subsequently, we performed a long-term (15 months) longitudinal cohort study in 10 Landrace–Yorkshire swine, in five of which HC and in five combined DM + HC were induced. VWF:Ag was higher at 15 months compared with 9 months in HC (0.37 [0.32–0.42] vs. 0.27 [0.23–0.40], p = 0.042) and DM + HC (0.33 [0.32–0.37] vs. 0.25 [0.24–0.33], p = 0.042). Both long-term groups had endothelial dysfunction compared with controls and atherosclerosis after 15 months. In conclusion, short-term hyperglycemia and dyslipidemia increase FVIII, independent of VWF. Long-term DM and HC increase VWF via endothelial dysfunction and atherosclerosis. Therefore, VWF seems to be a biomarker for advanced cardiovascular disease.


Sign in / Sign up

Export Citation Format

Share Document